Health Care Resource Use and Economic Burden in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy and Atrial Fibrillation
Open Access
- 2 September 2025
- journal article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (17) , e038755
Abstract
Background: Atrial fibrillation (AF) is common among patients with obstructive hypertrophic cardiomyopathy (oHCM), although the impact of AF on health care resource use and costs is not well defined. Methods: We performed a retrospective analysis of claims data from 2016 to 2021 and used International Classification of Diseases, Tenth Revision ( ICD‐10 ) codes to identify adult patients with symptomatic oHCM and classify their status with respect to AF as follows: (1) prevalent AF, (2) incident AF, and (3) no AF. Health care resource use and costs for each cohort were analyzed and expressed as per person per year (PPPY). Results: Of 22 216 patients with symptomatic oHCM, 6677 had prevalent AF (30.1%), 2879 had incident AF (13.0%), and 12 660 were without AF (57.0%). Patients with incident AF incurred mean total health care costs that were similar to those with prevalent AF but substantially greater than those without AF (mean, $66 619 [95% CI, $59 702–$74 336] versus $63 937 [95% CI, $59 803–$68 356] versus $46 686 [95% CI, $43 901–$49 648] per person per year, P <0.0001). After adjusting for age, sex, major comorbidities, and septal reduction therapy, mean total health care costs remained greater in the groups with incident and prevalent AF than the group without AF, with trends toward even greater relative costs in the group with incident AF. Similar trends were present in adjusted costs related to hospitalizations, surgeries, and urgent care. Conclusions: The diagnosis of AF in the setting of symptomatic oHCM not only has important implications for patient management but also substantial economic impacts, as it is associated with significantly greater health care costs and resource use relative to patients with symptomatic oHCM and no AF.Keywords
This publication has 31 references indexed in Scilit:
- Clinical Outcomes, Resource Utilization, and Treatment Over the Disease Course of Symptomatic Obstructive Hypertrophic Cardiomyopathy in the United StatesThe American Journal of Cardiology, 2023
- Healthcare utilization and costs associated with a diagnosis of incident atrial fibrillationHeart Rhythm O2, 2022
- Treatment Changes, Healthcare Resource Utilization, and Costs Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Database StudyCardiology and Therapy, 2022
- Healthcare resource utilization and cost of obstructive hypertrophic cardiomyopathy in a US populationAmerican Heart Journal Plus: Cardiology Research and Practice, 2022
- Clinical Significance of New-Onset Atrial Fibrillation in Patients with Hypertrophic CardiomyopathyESC Heart Failure, 2021
- Prevalence of Hypertrophic Cardiomyopathy in the UK Biobank PopulationJAMA Cardiology, 2021
- Burden and trends of arrhythmias in hypertrophic cardiomyopathy and its impact of mortality and resource utilizationJournal of Arrhythmia, 2019
- Economic Burden of Undiagnosed Nonvalvular Atrial Fibrillation in the United StatesThe American Journal of Cardiology, 2015
- A systematic review of validated methods for identifying atrial fibrillation using administrative dataPharmacoepidemiology and Drug Safety, 2012
- Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adultsThe American Journal of Medicine, 2004